A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if adding vericiguat to standard treatment for
cancer therapy related cardiac dysfunction (CTRCD) is more effective than standard treatment
alone. The addition of vericiguat to the usual treatment could help improve cardiac function,
but it could also cause side effects. This study will help researchers find out whether this
different treatment is better, the same as, or worse than the usual approach.